OncoMatch/Clinical Trials/NCT05405387
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Is NCT05405387 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Budesonide EC for multiple myeloma.
Treatment: Budesonide EC — A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Prior therapy
Cannot have received: oral budesonide
Ongoing or current use of oral budesonide at the time of enrollment
Cannot have received: allogenic stem cell transplant
Prior history of receiving an allogenic stem cell transplant
Lab requirements
Liver function
Total Bilirubin ≤ 2 x institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤ 5 × institutional ULN
Adequate organ function as defined as: Hepatic: Total Bilirubin ≤ 2 x institutional upper limit of normal (ULN). AST(SGOT)/ALT(SGPT) ≤ 5 × institutional ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute at the University of Utah · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05405387 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior oral budesonide, allogenic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages